Mean FSS scores returned to values comparable with baseline among patients receiving simeprevir/PR after Week @ in PILLAR ( after treatment completion for the majority of patients ) and in ASPIRE ( after Week @ ) , consistent with RGT enabling early termination of all treatment at Week @ in @ % of simeprevir/PR-treated patients in the PILLAR study .